JPRN-UMIN000037833招募中未知
All-Patient General Drug Use Surveillance of Rozlytrek Capsule - Advanced or recurrent solid tumors with NTRK gene fusions - - All-Patient General Drug Use Surveillance of Rozlytrek Capsule- Advanced or recurrent solid tumors with NTRK gene fusions
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Advanced or recurrent solid tumor patients with ROS1 gene fusions expected to receive Rozlytrek during the enrollment period
研究者
相似试验
招募中
不适用
All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancerROS1 fusion gene-positive unresectable advanced or metastatic non-small cell lung cancerJPRN-UMIN000039529Chugai Pharmaceutical Co. Ltd.200
招募中
不适用
All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancerJPRN-UMIN000046619Chugai Pharmaceutical Co. Ltd.200
招募中
不适用
General Drug Use Surveillance (All Patient Surveillance) of ENSPRYNG Syringes for Subcutaneous Injection - Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)JPRN-UMIN000041047Chugai Pharmaceutical Co. Ltd.330
招募中
不适用
General Drug Use Surveillance of RONAPREVE injection set (casirivimab [genetical recombination] and imdevimab [genetical recombination])- SARS-CoV-2 infection or prevention of onsetJPRN-UMIN000044927Chugai Pharmaceutical Co. Ltd.770
招募中
Unknown
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100